Vanguard Group Inc. Has $8.07 Billion Stock Position in Elevance Health, Inc. $ELV

Key Points

• Vanguard holds 23,019,518 shares of Elevance (about 10.36%), a stake valued at roughly $8.07 billion per its latest SEC filing.
• Elevance beat Q1 estimates with $12.58 EPS, raised its 2026 adjusted EPS outlook to at least $26.75, and drew analyst upgrades (e.g., Bernstein raised its price target to $424), signaling positive momentum.
• A law firm, Kirby McInerney, has opened an investor litigation probe into potential securities claims involving Elevance or its senior management, introducing legal risk and uncertainty for the stock.

Vanguard Group Inc. grew its holdings in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 0.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,019,518 shares of the company's stock after purchasing an additional 20,873 shares during the quarter. Vanguard Group Inc. owned about 10.36% of Elevance Health worth $8,069,492,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Physician Wealth Advisors Inc. lifted its position in shares of Elevance Health by 331.6% in the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company's stock worth $26,000 after buying an additional 63 shares during the last quarter. Rossby Financial LCC increased its holdings in shares of Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company's stock valued at $28,000 after acquiring an additional 44 shares during the last quarter. Activest Wealth Management raised its stake in shares of Elevance Health by 66.7% in the 3rd quarter. Activest Wealth Management now owns 85 shares of the company's stock valued at $27,000 after acquiring an additional 34 shares in the last quarter. Motco lifted its holdings in Elevance Health by 334.8% in the 3rd quarter. Motco now owns 100 shares of the company's stock worth $32,000 after purchasing an additional 77 shares during the last quarter. Finally, ORG Partners LLC lifted its holdings in Elevance Health by 120.4% in the 4th quarter. ORG Partners LLC now owns 108 shares of the company's stock worth $38,000 after purchasing an additional 59 shares during the last quarter. 89.24% of the stock is currently owned by institutional investors.

Elevance Health Price Performance

Shares of NYSE:ELV opened at $344.64 on Monday. The firm has a market capitalization of $74.84 billion, a PE ratio of 14.66, a PEG ratio of 2.06 and a beta of 0.49. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $427.54. The business's 50 day moving average is $308.96 and its 200-day moving average is $331.22.

Elevance Health (NYSE:ELV - Get Free Report) last issued its earnings results on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, beating analysts' consensus estimates of $10.74 by $1.84. The business had revenue of $49.49 billion during the quarter, compared to analyst estimates of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.Elevance Health's revenue was up 1.5% on a year-over-year basis. During the same period in the prior year, the company posted $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Sell-side analysts predict that Elevance Health, Inc. will post 26.81 earnings per share for the current year.

Elevance Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be paid a $1.72 dividend. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. Elevance Health's dividend payout ratio is currently 29.26%.

Key Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q1 beat and upgraded outlook — ELV reported strong Q1 results (EPS $12.58 vs. estimates) and raised its 2026 adjusted EPS outlook to at least $26.75 while targeting ~12% EPS growth in 2027, which supports earnings upside and margin improvement. Elevance raises 2026 outlook
• Positive Sentiment: Large analyst upgrade — Sanford C. Bernstein raised its price target to $424 and kept an "outperform" rating, implying ~23% upside; a high-conviction bullish call that can attract demand. Bernstein raises PT to $424
• Positive Sentiment: Barclays reiteration of Buy — Barclays stuck with a Buy rating, signaling institutional confidence that can provide support for the shares. Barclays sticks to Buy
• Positive Sentiment: Operational tailwinds noted — Management highlighted medical cost controls and AI-driven margin expansion, and major outlets reported the company raised its annual profit forecast on those controls, reinforcing the positive earnings message. Profit forecast raised on cost controls
• Neutral Sentiment: Mixed analyst PT lifts with conservative ratings — Several firms nudged up targets but kept neutral/hold stances (Goldman to $370 neutral; Deutsche Bank to $363 hold; Evercore to $360 in-line). These raise reference prices but signal measured optimism. Goldman raises PT to $370
• Neutral Sentiment: Jefferies update — Jefferies revised its forecasts after a deeper look at exchange-segment dynamics and trimmed its PT slightly; this is an analyst reshuffle rather than a directional shock. Jefferies updates forecasts
• Negative Sentiment: Investor litigation probe — Law firm Kirby McInerney has opened an investigation into potential securities claims involving Elevance and/or its senior management; legal scrutiny can pressure the stock and raise uncertainty. Kirby McInerney investor alert
• Negative Sentiment: Some broker nuance implies limited near-term upside — Robert W. Baird's update leaves a neutral stance with a lower relative target vs. some peers, noting limited immediate upside which can cap buying interest. Baird adjusts PT

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Robert W. Baird increased their price target on Elevance Health from $317.00 to $331.00 and gave the company a "neutral" rating in a report on Thursday. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Elevance Health from $332.00 to $363.00 and gave the stock a "hold" rating in a research report on Thursday. Truist Financial lowered their price target on Elevance Health from $390.00 to $375.00 and set a "buy" rating on the stock in a research report on Monday, April 13th. Royal Bank Of Canada lowered Elevance Health from an "outperform" rating to a "sector perform" rating and set a $358.00 price objective on the stock. in a research note on Tuesday, February 3rd. Finally, Wells Fargo & Company cut their price objective on Elevance Health from $424.00 to $391.00 and set an "overweight" rating for the company in a research report on Friday, January 30th. Eleven research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to MarketBeat.com, Elevance Health presently has a consensus rating of "Moderate Buy" and a consensus price target of $380.42.

Elevance Health Company Profile

Elevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.

Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.